News

image158

THE OCTAVIAN SEMINAR 2019

January 17 -19, 2019: This year’s seminar in Zurich and Flims, the second in our history, was another important milestone for the Octavian Team. We are pleased with the achieved result: Over the three days we welcomed 32 companies and more than 80 clients, which interconnected and interfaced to gain insightful and valuable information and investment ideas. 


We hope our efforts delivered results of quality. Once more, we would like to recall that our seminar rests on 20+ years of legacy from our former employer; as such, we are committed to make the  Octavian Seminar a tradition that will  honor that legacy and that will continue to deliver ideas, insight and high - quality interactions. As always, we hope to have some fun along the way.


We thank all participating companies and investor clients for their continued trust and support. 


Team Octavian looks forward to the next Octavian Seminar, which will take place on January 16 - 18, 2020. Please save-the-date.

image159

Octavian Top 5 for Q1 2019

January 3, 2018: Today we publish our TOP 5 list for Q1 2018. Subscribers can access the full report on the RSRCHX platform via the link below and on our Bloomberg homepage {OCTV <GO>}


Link to  TOP 5 Q1 2019 report on RSRCHX


If you cannot access the report please do not hesitate to contact us at sales@octavian.ch

image160

Kuros ends transformational year

December 17, 2018: Kuros ends transformational year with first MagnetOs sales, lead clinical program on track, and successful capital raise.


Kuros successfully raised CHF 16.1 million from existing and new investors. (read more)


Octavian was acting as Joint Placement Agent 

image161

Poenina successfully completes its CHF 35 million rights offering

November 2, 2018: Poenina Holding AG (PNHO.SW) today announced the successful completion of its CHF 35 million rights offering to fund the acquisition of the Inretis Group.


Link to Poenina's press release (in German language only)


Octavian was acting as Selling Agent

image162

Octavian Top 5 for Q4 2018

October 1, 2018: Today we publish our TOP 5 list for Q4 2018. Subscribers can access the full report on the RSRCHX platform via the link below and on our Bloomberg homepage {OCTV <GO>}


Link to  TOP 5 Q4 2018 report on RSRCHX


If you cannot access the report please do not hesitate to contact us at sales@octavian.ch

image163

Idorsia successfully completes the offering of new shares and convertible bonds

July 11, 2018: Idorsia Ltd (IDIA.SW) today announced that it has successfully placed  11,912,000 new shares, corresponding to  approximately 10% of Idorsia's currently issued share capital, by way of  an accelerated bookbuilding. Additionally, Idorsia successfully placed  CHF 200 million of senior unsecured convertible bonds due  2024. 


Link to Idorsia's press release


Octavian was acting as Selling Agent

image164

Octavian Top 5 for Q3 2018

July 2, 2018:  Today we publish our TOP 5 List for Q3 2018. The full report can be  accessed through the RSRCHX platform via the link below and on our  Bloomberg homepage {OCTV <GO>}


Link to report on RSRCHX


If you cannot access the report please do not hesitate to contact us at sales@octavian.ch

image165

Polyphor prices its IPO at CHF 38 per share and lists on SIX Swiss Exchange

May 15, 2018:  Polyphor Ltd ("Polyphor" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative antibiotics and other specialty pharma products for severe or life-threatening diseases, today set the offer price for its shares in the initial public offering (“IPO”) at CHF 38 per share, at the upper end of the offer price range.  


Link to POLN's press release


Octavian was acting as Selling Agent

image166

Octavian Top 5 for Q2 2018

April 2, 2018: Today we publish our TOP 5 List for Q2 2018. The full report can be accessed through the RSRCHX platform via the link below and on our Bloomberg homepage {OCTV <GO>}


Link to report on RSRCHX


If you cannot access the report please do not hesitate to contact us at sales@octavian.ch

image167

Addex Sucessfully Raises CHF40 million in Capital Increase

March 29, 2018: Addex Therapeutics (SIX: ADXN), the leading developer of oral allosteric modulators for neurological disorders, announced today that the company has successfully completed its capital increase, raising CHF40 million.


Link to ADXN's press release


Octavian was acting as Placement Agent.

image168

OCTAVIAN SEMINAR 2018

January 20, 2018: A big thank you to all of the companies and investors that attended the OCTAVIAN SEMINAR 2018 in Zurich and Flims. 


Please save the date for the next one:

OCTAVIAN SEMINAR 2019

January 17-19, 2019


Now off to the slopes...

image169

Octavian Top 5 for Q1 2018

January 2, 2018: Our Top 5 for Q1 2018 can now be accessed through the RSRCHX platform via the link below and on  our Bloomberg homepage {OCTV <GO>}


Link to report on RSRCHX


If you cannot access the report please do not hesitate to contact us at sales@octavian.ch

image170

Octavian on stage at the inaugural Swiss IPO Day 2017

November 28, 2017: Octavian presents on stage in front of 15 grownup Swiss startup companies at the inaugural Swiss IPO Day 2017. Many thanks to the organizers at Swiss Startup Invest for this unconventional and refreshing event.  

image171

ADC Therapeutics Announces Closing of $200 Million Private Financing

 

October 23, 2017: The Octavian team congratulates ADC Therapeutics (ADCT), an  oncology drug development company that specializes in the development of  proprietary PBD-based Antibody Drug Conjugates targeting major cancers,  to the successful raise of $200 million through a private placement.  Octavian supported ADCT in this private placement with targeted access  to its investor client base resulting in the addition of new quality  investors to ADCT’s shareholder registry.


Link to ADCT's press release

image172

Octavian Top 5 for Q4 2017

 

October 2, 2017: We are delighted to bring you the second installment of our  quarterly top 5 picks as Team Octavian. The full report  can be a  accessed on the following link:


Link to full report on RSRCHX

image173

Octavian Top 5 for Q3 2017

July 3, 2017: We are delighted to present you with our first TOP 5 List for Q3 2017 under the Octavian name. The full report can be accessed through the RSRCHX platform via the link below.


Link to report on RSRCHX

image174

Kuros Biosciences strengthens equity base with placement of new shares

June 29, 2017: Kuros Biosciences AG (SIX:KURN) today announced the final terms of its "at market" rights and share offering. The Octavian team (formerly Bank am Bellevue) was supporting Kuros Bioscience in this placement. 


Press release

image175

Octavian initiates research coverage on Galenica

May 16, 2017: Octavian publishes its first research report on RSRXCH with the initiation of coverage note on Galenica (SIX:GALN). Bank am Bellevue, the former employer of the Octavian founder team acted as Co-Lead Manager in the IPO of Galenica Santé on SIX Swiss Exchange in April 2017.


Link to report on RSRCHXCHANGE